Evidence map›Paper›PMID 40290076›Full record

ArticleESC heart failure2025

Multiomics insight into the role of glucagon-like peptide-1 receptor agonists in heart failure.

Yuhang Tao, Qi Liu, Yuxing Wang, Yingchao Gong, Mingying Xu, Ruhong Jiang, Kai Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuhang TaoDepartment of Cardiology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, China.
Qi LiuDepartment of Cardiology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, China.
Yuxing WangDepartment of Emergency Medicine, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Yingchao GongDepartment of Cardiology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, China.
Mingying XuDepartment of General Practice, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Ruhong JiangDepartment of Cardiology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, China.
Kai ZhangDepartment of Cardiology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, China.ORCID https://orcid.org/0000-0002-2747-3962

Funding

National Natural Science Foundation of China 82200343National Natural Science Foundation of China 82200434
6 · The paper itself

Abstract

aimsCardiovascular diseases, such as atrial fibrillation, coronary artery disease, heart failure (HF) and ischaemic stroke, are leading causes of death globally and exert major global health burden. Recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP1Ra), a novel class of antidiabetic drugs, may not only help manage blood glucose but also reduce the risks of cardiovascular diseases. However, the mechanisms through which GLP1Ra protects against cardiovascular diseases, remain incompletely understood. METHODS AND

resultsGenome-wide association study dates were used to investigate the impact of GLP1Ra on cardiovascular diseases, including atrial fibrillation (1,202,168 European and 28,612 East Asian), coronary artery disease (501,756 European and 183,134 East Asian), heart failure (HF) (1,350,497 European and 203,040 East Asian) and ischaemic stroke (689,168 European and 192,383 East Asian). Genetic instruments were selected from the GLP1R gene region, and two-sample Mendelian randomization (MR) analyses were conducted to assess the causal effects of GLP1Ra on cardiovascular diseases in European and East Asian populations. Summary-data-based MR analyses were performed for further validation using expression quantitative trait loci data. Mediation analysis evaluates the role of circulating inflammatory proteins and metabolites in mediating the effects of GLP1Ra. Meantime, we performed a series of sensitivity analyses to confirm the robustness of the results. The result demonstrated significant causal association between GLP1Ra and HF in European populations (odds ratio: 0.60, 95% CI 0.51-0.72, P = 2.76 × 10

conclusionsThis study provides multiomics insight into the role of GLP1Ra in cardiovascular diseases, especially in HF and the underlying pathway. The results suggest that GLP1Ra may exert anti-HF effects by reducing the concentration of circulating FGF5 and increasing the levels of circulating NAC, and enriches the potential mechanisms through which GLP1Ra alleviates HF.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHeart FailureGenome-Wide Association StudyGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsMendelian Randomization AnalysisMultiomicsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGLP‐1 agonistHeart failureInflammatory cytokinesMendelian randomizationMetabolomics

Identifiers

PMID40290076
PMCPMC12287862

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.